Form 4: Tevogen Bio CFO Kirti Desai Granted 750,000 Restricted Shares Under New Incentive Plan

Tevogen Bio Holdings Inc.'s Chief Financial Officer, Kirti Desai, was granted 750,000 shares of common stock as restricted stock, vesting over three years starting in 2030.

Summary

• Kirti Desai, Chief Financial Officer of Tevogen Bio Holdings Inc. (TVGN), acquired 750,000 shares of common stock.
• The acquisition occurred on June 27, 2025, at a price of $0 per share, indicating a grant.
• The shares represent a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The granted shares will vest ratably in three equal annual installments, commencing on June 27, 2030.
• Vesting is conditional upon the reporting person remaining in service with the Issuer at the specified vesting dates.
• Following this transaction, Kirti Desai beneficially owns a total of 10,449,186 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates management alignment and retention efforts, which are generally favorable. However, it's a routine compensation event rather than a significant operational or financial breakthrough.

Positives

• The grant of restricted stock aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing sustained performance.
• The transaction is part of the 2024 Omnibus Incentive Plan, indicating a structured approach to executive compensation and retention.

Negatives

• The grant of 750,000 shares, while restricted, represents potential future dilution for existing shareholders upon vesting.

Risks

• The vesting of the restricted stock is contingent upon the reporting person remaining in service with the Issuer, posing a risk to the full realization of the grant if employment ceases.

Future Outlook

The grant of restricted stock with a long vesting period commencing in 2030 indicates a long-term commitment from the Chief Financial Officer to the company's future performance and strategic objectives.

Industry Context

Executive compensation through restricted stock grants is a common practice in the biotechnology and pharmaceutical industries, aiming to retain key talent and align management incentives with long-term shareholder value creation. The use of an Omnibus Incentive Plan is standard for publicly traded companies to manage equity-based compensation.

Comparison to Industry Standards

• The use of restricted stock grants as a component of executive compensation is a standard practice across various industries, including biotechnology, to incentivize long-term performance and retention.
• The vesting schedule, while long-dated, is designed to ensure continued service and commitment, a common feature in such plans.
• The grant under an 'Omnibus Incentive Plan' is typical for public companies, providing flexibility in awarding various types of equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the CFO's interests with shareholders for long-term value creation but also introduces potential future dilution upon vesting of the shares.
• Employees: The existence of an Omnibus Incentive Plan suggests a framework for broader employee equity compensation, potentially boosting morale and retention.

Next Steps

• The restricted stock will begin vesting in three equal annual installments starting on June 27, 2030, provided the CFO remains in service.

Key Dates

Keywords

Tevogen Bio Holdings Inc., TVGN, Kirti Desai, Chief Financial Officer, Restricted Stock, Stock Grant, Incentive Plan, SEC Form 4, Insider Transaction, Executive Compensation